Hemozoin crystallization pathway

The hemozoin crystallization pathway is a vital metabolic process in Plasmodium parasites, the causative agents of malaria, occurring during their intraerythrocytic development (Sullivan, 2002; PubMed: 12456506). As the parasite consumes host hemoglobin to obtain amino acids, it releases free heme (ferriprotoporphyrin IX), which is highly toxic and can cause oxidative damage to parasite membranes (Hempelmann, 2007; PubMed: 17651301). To survive, the parasite detoxifies this heme by sequestering it into an insoluble, crystalline form known as hemozoin or malaria pigment (Pagola et al., 2000; Nature). This pathway is the primary target for quinoline-based antimalarials, such as chloroquine and quinine, which accumulate in the parasite's acidic food vacuole (Egan, 2008; PubMed: 18624470). These drugs bind to the surface of growing hemozoin crystals or to free heme, preventing further crystallization and leading to the accumulation of toxic heme species that kill the parasite (Combrinck et al., 2013; PubMed: 23716110). Despite its importance, the clinical utility of targeting this pathway is threatened by the widespread emergence of drug resistance, primarily through mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) (Fidock et al., 2000; PubMed: 11000114). New therapeutic strategies continue to explore this pathway due to its absence in human physiology, making it an ideal target for selective toxicity (Weissbuch & Leiserowitz, 2008; Chemical Reviews). Monitoring hemozoin levels and parasite clearance remains a standard method for evaluating drug efficacy in clinical settings (Ambele et al., 2012; PubMed: 22457358).

Other names

Heme detoxification pathwayHeme biocrystallizationMalaria pigment formationFerriprotoporphyrin IX sequestration

Inhibition of hemozoin crystal growth by binding to crystal faces or forming complexes with free ferriprotoporphyrin IX, leading to toxic heme accumulation.